CD40LG and COVID-19: We recently conducted a population-based study to determine the prevalence of IgM and IgG antibodies against SARS-CoV-2, as well as COVID-19–related clinical manifestations, in 673 community-dwelling middle-aged and older adults enrolled in the Atahualpa Project cohort.10 In that study, we demonstrated a seroprevalence of 45% and clinical manifestations consistent with COVID-19 in 77% of the seropositive individuals.